Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
16206 | 667 | 46.5 | 87% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
419 | 3 | ADENOVIRUS//MERKEL CELL CARCINOMA//GENE THERAPY | 28518 |
564 | 2 | GENE THERAPY//ADENOVIRUS//HUMAN GENE THERAPY | 14456 |
16206 | 1 | GENE MED GRP//GENEMED GRP//EXPT TREATMENT CYST FIBROSIS | 667 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | GENE MED GRP | address | 426762 | 3% | 55% | 17 |
2 | GENEMED GRP | address | 235432 | 1% | 86% | 6 |
3 | EXPT TREATMENT CYST FIBROSIS | address | 219724 | 2% | 40% | 12 |
4 | UK CYST FIBROSIS GENE THER Y CONSORTIUM | address | 190744 | 1% | 83% | 5 |
5 | AIRWAY GENE TRANSFER | authKW | 183115 | 1% | 100% | 4 |
6 | PROGRAM GENE THER Y | address | 177542 | 2% | 24% | 16 |
7 | ION TRANSPORT UNIT | address | 172335 | 1% | 47% | 8 |
8 | CYSTIC FIBROSIS GENETICS THERAPY | authKW | 137337 | 0% | 100% | 3 |
9 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENETICS THERAPEUTIC USE | authKW | 137337 | 0% | 100% | 3 |
10 | GRP LUNG DEV | address | 126766 | 1% | 46% | 6 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Medicine, Research & Experimental | 10366 | 46% | 0% | 309 |
2 | Genetics & Heredity | 7045 | 43% | 0% | 285 |
3 | Biotechnology & Applied Microbiology | 6935 | 43% | 0% | 288 |
4 | Respiratory System | 2232 | 15% | 0% | 103 |
5 | Biochemistry & Molecular Biology | 461 | 25% | 0% | 167 |
6 | Critical Care Medicine | 123 | 3% | 0% | 20 |
7 | Pharmacology & Pharmacy | 101 | 10% | 0% | 65 |
8 | Cell Biology | 59 | 7% | 0% | 46 |
9 | Materials Science, Biomaterials | 58 | 2% | 0% | 12 |
10 | Virology | 40 | 2% | 0% | 16 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GENE MED GRP | 426762 | 3% | 55% | 17 |
2 | GENEMED GRP | 235432 | 1% | 86% | 6 |
3 | EXPT TREATMENT CYST FIBROSIS | 219724 | 2% | 40% | 12 |
4 | UK CYST FIBROSIS GENE THER Y CONSORTIUM | 190744 | 1% | 83% | 5 |
5 | PROGRAM GENE THER Y | 177542 | 2% | 24% | 16 |
6 | ION TRANSPORT UNIT | 172335 | 1% | 47% | 8 |
7 | GRP LUNG DEV | 126766 | 1% | 46% | 6 |
8 | MOL PULMONOL | 124612 | 1% | 39% | 7 |
9 | REG RIFERIMENTO FIBROSI CIST | 91558 | 0% | 100% | 2 |
10 | CF PULM TREATMENT | 74902 | 1% | 27% | 6 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HUMAN GENE THERAPY | 103979 | 13% | 3% | 87 |
2 | GENE THERAPY | 90635 | 13% | 2% | 88 |
3 | JOURNAL OF GENE MEDICINE | 42187 | 5% | 3% | 36 |
4 | MOLECULAR THERAPY | 14033 | 5% | 1% | 33 |
5 | AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY | 7583 | 4% | 1% | 29 |
6 | CURRENT OPINION IN MOLECULAR THERAPEUTICS | 4230 | 1% | 1% | 9 |
7 | JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 3437 | 1% | 1% | 7 |
8 | HUMAN GENE THERAPY CLINICAL DEVELOPMENT | 2257 | 0% | 2% | 2 |
9 | MOLECULAR THERAPY-NUCLEIC ACIDS | 1358 | 0% | 1% | 3 |
10 | CURRENT GENE THERAPY | 1329 | 1% | 1% | 4 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PAUL-SMITH, MC , BELL, RV , ALTON, WE , ALTON, EWFW , GRIESENBACH, U , (2016) GENE THERAPY FOR CYSTIC FIBROSIS: RECENT PROGRESS AND CURRENT AIMS.EXPERT OPINION ON ORPHAN DRUGS. VOL. 4. ISSUE 6. P. 649 -658 | 37 | 57% | 3 |
2 | GRIESENBACH, U , PYTEL, KM , ALTON, EWFW , (2015) CYSTIC FIBROSIS GENE THERAPY IN THE UK AND ELSEWHERE.HUMAN GENE THERAPY. VOL. 26. ISSUE 5. P. 266 -275 | 48 | 44% | 13 |
3 | WEISS, DJ , PILEWSKI, JM , (2003) THE STATUS OF GENE THERAPY FOR CYSTIC FIBROSIS.SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. VOL. 24. ISSUE 6. P. 749-770 | 88 | 40% | 6 |
4 | GRIESENBACH, U , ALTON, EWFW , (2009) GENE TRANSFER TO THE LUNG: LESSONS LEARNED FROM MORE THAN 2 DECADES OF CF GENE THERAPY.ADVANCED DRUG DELIVERY REVIEWS. VOL. 61. ISSUE 2. P. 128-139 | 54 | 45% | 73 |
5 | KIM, N , DUNCAN, GA , HANES, J , SUK, JS , (2016) BARRIERS TO INHALED GENE THERAPY OF OBSTRUCTIVE LUNG DISEASES: A REVIEW.JOURNAL OF CONTROLLED RELEASE. VOL. 240. ISSUE . P. 465 -488 | 89 | 23% | 1 |
6 | ALTON, EWFW , ARMSTRONG, DK , ASHBY, D , BAYFIELD, KJ , BILTON, D , BLOOMFIELD, EV , BOYD, AC , BRAND, J , BUCHAN, R , CALCEDO, R , ET AL (2015) REPEATED NEBULISATION OF NON-VIRAL CFTR GENE THERAPY IN PATIENTS WITH CYSTIC FIBROSIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B TRIAL.LANCET RESPIRATORY MEDICINE. VOL. 3. ISSUE 9. P. 684 -691 | 16 | 73% | 56 |
7 | ARMSTRONG, DK , CUNNINGHAM, S , DAVIES, JC , ALTON, EWFW , (2014) GENE THERAPY IN CYSTIC FIBROSIS.ARCHIVES OF DISEASE IN CHILDHOOD. VOL. 99. ISSUE 5. P. 465 -468 | 27 | 66% | 19 |
8 | ANEJA, MK , GEIGER, JP , HIMMEL, A , RUDOLPH, C , (2009) TARGETED GENE DELIVERY TO THE LUNG.EXPERT OPINION ON DRUG DELIVERY. VOL. 6. ISSUE 6. P. 567-583 | 58 | 39% | 13 |
9 | MCLACHLAN, G , DAVIDSON, H , HOLDER, E , DAVIES, LA , PRINGLE, IA , SUMNER-JONES, SG , BAKER, A , TENNANT, P , GORDON, C , VRETTOU, C , ET AL (2011) PRE-CLINICAL EVALUATION OF THREE NON-VIRAL GENE TRANSFER AGENTS FOR CYSTIC FIBROSIS AFTER AEROSOL DELIVERY TO THE OVINE LUNG.GENE THERAPY. VOL. 18. ISSUE 10. P. 996-1005 | 24 | 77% | 49 |
10 | GRIESENBACH, U , ALTON, EWFW , (2013) MOVING FORWARD: CYSTIC FIBROSIS GENE THERAPY.HUMAN MOLECULAR GENETICS. VOL. 22. ISSUE . P. R52-R58 | 32 | 57% | 20 |
Classes with closest relation at Level 1 |